GSK3A and neoplasm: Consistent with in vitro data, we demonstrate that temporal pharmacologic activation of WNT/β-catenin signaling by treatment with the GSK3α/β inhibitor CHIR99021 markedly decreases melanoma tumor growth by inhibiting proliferation and inducing apoptosis also in GEMM of melanoma (Fig. 7).